Discovering Breakthrough Treatments for Human Disease
Dr. Sands co-founded Lexicon and has been our president and chief executive officer and a director since September 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery to bring innovative drugs to patients. He has overseen the evolution of Lexicon from a research-stage company to a drug development company, including implementing the strategy to integrate chemistry capabilities with Lexicon's powerful genetics platform to create a unique drug discovery engine. Dr. Sands was also instrumental in establishing Lexicon's major alliances with pharmaceutical companies as well as implementing the company's financing strategy. With Dr. Zambrowicz, he has co-authored numerous publications focusing on gene knockout technology, drug discovery and drug development. Before founding Lexicon, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. He received his B.A. in economics and political science from Yale University and his M.D. and Ph.D. from Baylor College of Medicine where he studied gene knockout technology and tissue-specific gene regulation in transgenic mice.
Dr. Zambrowicz has been our executive vice president and chief scientific officer since February 2007. Dr. Zambrowicz served as our executive vice president of research from August 2002 to February 2007, senior vice president of genomics from February 2000 to August 2002, vice president of research from January 1998 to February 2000, and senior scientist from April 1996 to January 1998. Dr. Zambrowicz has been instrumental in the development of our proprietary gene trapping technology, target validation methods, and small molecule drug discovery platform. Dr. Zambrowicz is responsible for the discovery of new drug candidates and clinical development through Phase 2 human proof-of-concept. Under his direction, Lexicon has knocked out and analyzed nearly 5,000 genes, resulting in more than 100 potential drug targets, and brought multiple clinical candidates into development. With Dr. Sands, he has co-authored numerous scientific and drug development publications focusing on gene knockout technology and drug discovery. Prior to joining Lexicon, Dr. Zambrowicz served as a National Institutes of Health postdoctoral fellow at the Fred Hutchinson Cancer Center in Seattle, Washington, where he studied gene trapping and gene targeting technology. He received his B.S. in biochemistry from the University of Wisconsin. He received his Ph.D. in biochemistry from the University of Washington, where he studied tissue-specific gene regulation using transgenic mice.
Mr. Wade has been our executive vice president and chief financial officer since May 2010. He previously served as our executive vice president and general counsel from February 2000 to May 2010 and was our senior vice president and chief financial officer from January 1999 to February 2000. During his tenure with Lexicon, he has played an instrumental role in designing and negotiating corporate finance and securities transactions including the company’s initial public offering in April 2000 and private equity financing with Invus, L.P. in August 2007; the acquisition of Coelacanth Corporation that established the basis for our small molecule drug discovery efforts; and collaborations and licenses. Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries, as well as venture capital and investment banking firms. Mr. Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute. He received his B.A. and J.D. from The University of Texas.
Dr. Main has been our executive vice president of pharmaceutical research since February 2007 and served as our senior vice president from July 2001 to February 2007. Dr. Main established the Medicinal Chemistry operations based in Princeton, New Jersey which are responsible for the design, synthesis, and preclinical testing of all of our small molecule drug candidates in preparation for human clinical trials. In addition, Dr. Main has played a key role the design and implementation of our scientific strategy and prioritization of our small molecule drug discovery portfolio. Prior to joining Lexicon, Dr. Main was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development. Lexicon acquired Coelacanth Corporation in July 2001 to bring together the powerful biology and chemistry technologies necessary to create a revolutionary new pharmaceutical company. Prior to Coelacanth, Dr. Main spent more than 20 years in the discovery and development of novel drugs at Novartis Pharmaceuticals Corporation where he was formerly senior vice president, U.S. Research. Dr. Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England and completed postdoctoral studies with the Nobel Laureate Prof. R.B. Woodward, at the Woodward Research Institute in Basel, Switzerland.
Dr. Lapuerta has been our executive vice president of clinical development and chief medical officer since March 2013 and served as our senior vice president of clinical development and chief medical officer from March 2011 until March 2013. He is responsible for directing clinical development of Lexicon’s drug candidates from Phase 2 proof-of-concept through Phase 3 and approval. Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles in drug development, including global medical affairs and outcomes research strategy across multiple therapeutic areas, including cardiovascular disease, endocrinology, gastroenterology, and neurology at Bristol-Myers Squibb. From 2009 through 2010, Dr. Lapuerta served as vice president at Bristol-Myers Squibb where he was responsible for global development of an Alzheimer’s disease drug candidate with the associated use of an innovative biomarker. From 2007 through 2009, Dr. Lapuerta was senior vice president and chief medical officer at Cogentus Pharmaceuticals, a biotechnology company. Dr. Lapuerta received a B.S. from Harvard College and an M.D. from Harvard Medical School. He completed his training in internal medicine at the University of North Carolina at Chapel Hill followed by a post-doctoral research fellowship at the University of California at Los Angeles in neuroscience. He served as assistant professor at the University of Southern California School of Medicine for several years. He has published numerous scientific articles on a wide range of topics including clinical trials, drug safety, epidemiology, health economics, and quality of care.
Mr. Tessmer has been our vice president of finance and accounting since November 2007. He previously served as our senior director of finance from February 2004 to November 2007 and director of finance from April 2001 to February 2004. Mr. Tessmer is currently responsible for our financial reporting and analysis, accounting, risk management, treasury and tax functions. Prior to joining Lexicon, he was assistant controller for Mariner Health Network, Inc. from January 1997 to April 2001, and prior to that, he served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation. Mr. Tessmer is a certified public accountant and received his B.B.A. from the University of Wisconsin – Milwaukee and his M.B.A. from the University of Houston.